Loading...
Loading...
RGNX| Name | Value |
|---|---|
| Revenues | 24.2M |
| Cost of Revenue | 12.4M |
| Gross Profit | 11.8M |
| Operating Expense | 73.9M |
| Operating I/L | -62.1M |
| Other Income/Expense | 2.5M |
| Interest Income | 0.0M |
| Pretax | -59.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -59.6M |
REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy product candidates. The company's proprietary NAV Technology Platform utilizes adeno-associated virus gene delivery to address genetic defects and enable cells to produce therapeutic proteins or antibodies. Its lead product candidate, RGX-314, is in Phase III clinical trial for wet age-related macular degeneration. Additionally, the company is developing gene therapy product candidates for various genetic diseases, including mucopolysaccharidosis, neuronal ceroid lipofuscinosis, and Duchenne muscular dystrophy. REGENXBIO also generates revenue by licensing its NAV Technology Platform to other biotechnology and pharmaceutical companies and through collaboration and license agreements with partners.
